Veru Stock Gains After Q3 Result Tops Estimates

  • Veru Inc VERU reported third-quarter FY21 sales growth of 71% year-on-year, to $17.66 million, beating the analyst consensus of $14.10 million.
  • FC2 prescription net revenues climbed 150% Y/Y to $13.5 million.
  • Gross Profit increased 113% Y/Y to $14 million with a profit margin expanding 1600 basis points to 79%.
  • The operating loss widened to $(2.9) million as operating expenses more than doubled to $16.7 million.
  • The company held $123 million in cash and equivalents as of June 30, 2021.
  • Loss per share of $(0.03) beat the analyst consensus of $(0.06).
  • "Unfortunately, yet another COVID-19 viral infection wave has hit the United States and globally, making our COVID-19 drug development program highly relevant and timely as COVID-19 remains a severe threat with few effective therapies to complement the COVID-19 vaccination strategy," said CEO Mitchell Steiner.
  • Price Action: VERU shares are trading higher by 7.90% at $7.51 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLong IdeasNewsSmall CapMoversTrading IdeasBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!